U.S., Europe, Japan Look to Speed Up Drug Reviews
Dennis Normile and Eliot Marshall
TOKYO--Drug companies are hoping to save time and money by submitting the same safety and efficacy data to regulators in each of the three leading global markets. This fall, if all goes well, officials from the United States, Europe, and Japan will agree on a common drug review application form in hope of speeding the delivery of new treatments and, perhaps, lowering the cost to consumers.